Company intelligence / Profile preview

X4 Therapeutics

Boston, Massachusetts, United States

Ownership: Private
Employees: ~80
Development stage: Other

Overview

X4 Pharmaceuticals developed mavorixafor (Xolremdi), an oral once-daily selective antagonist of CXCR4, which received FDA approval in 2024 for the treatment of patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency. The drug showed efficacy in increasing circulating neutrophils and lymphocytes and had positive clinical results in Phase 3 trials. The company also explored applications in chronic neutropenia and other rare hematological and immunological disorders, with chronic neutropenia programs reaching late-stage clinical trials. In May 2024, Organon acquired X4 Pharmaceuticals.

Therapeutic areas: HematologyImmunologyInfectious DiseasesOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

NorgineStifel

Beyond the preview

Go deeper on X4 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on X4 Therapeutics.

Explore the full profile